Recent advances in molecular pathogenesis have identified activating mutations in the mitogen-activated protein kinase (MAPK) pathway, most notably BRAF V600E (present in approximately 60% of cases), establishing LCH as a clonal neoplastic process rather than a primary inflammatory disorder as historically considered [1]. The gene discussed is BRAF; the disease is Langerhans cell histiocytosis.